Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05721248

STOP-HER2: Stopping Trastuzumab in HER2+ MBC

The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients With HER2+ Metastatic Breast Cancer

Sponsor: Dana-Farber Cancer Institute

Conditions Breast Cancer HER2-positive Breast Cancer Metastatic Breast Cancer

Interventions Cessation of anti-HER2 treatment

Updated 13 times since 2023 Last updated: Feb 18, 2026 Started: Apr 19, 2023 Primary completion: Jun 30, 2026 Completion: Jun 30, 2036

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05721248, this PHASE2 trial focuses on Breast Cancer and HER2-positive Breast Cancer and remains ongoing. Sponsored by Dana-Farber Cancer Institute, it has been updated 13 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

13 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE2
Sep 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Oct 2024 — Sep 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2

▶ Show 8 earlier versions

Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Feb 2024 — Jun 2024 [monthly]

Recruiting PHASE2
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Jan 2024 [monthly]

Recruiting PHASE2
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE2
May 2023 — Oct 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Mar 2023 — May 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dana-Farber Cancer Institute
Gateway for Cancer Research
Johns Hopkins University
National Cancer Institute (NCI)
Susan G. Komen Breast Cancer Foundation
Translational Breast Cancer Research Consortium

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Durham, United States , Foxborough, United States , Houston, United States , Jacksonville, United States , Methuen, United States , Milford, United States , Phoenix, United States , Pittsburgh, United States , Rochester, United States and 3 more locations